[Psychotropic and cognitive effects of topiramate in the treatment of epileptic patients].
To study a character of topiramate (TPM) effect on psychopathological and neurocognitive processes in patients with temporal partial epilepsy, 83 patients (33 men and 50 women, mean age 29.1 +/- 10.6 years) were examined. Fifty-three patients were diagnosed with temporal cryptogenic epilepsy and 20 with temporal symptomatic epilepsy. Thirty-three patients received TPM (124 +/- 35.6 mg daily), 26--carbamazepine (819 +/- 274.2 mg daily), 15--phenobarbital (154.6 +/- 95.1 mg daily) and 11 patients received no therapy. The statistically significant difference between the groups treated with TPM and phenobarbital were found only for cognitive traits (total MMT scores, total scores on the executive functions scale, latencies of positive and negative answers in WCST, verbal fluency). TPM was more effective than phenobarbital for all traits, with the exception of verbal fluency. The comparison of patients by some parameters before and during the treatment with TPM revealed the favorable effect of the drug in the reduction of obsessive symptoms, aggressiveness and social isolation on the SCL-90 as well as higher scores on the executive functions scale and the lower latency of positive answer in WCST. The monotherapy with TPM leads to the improvement of executive functions, reduction of aggressive and obsessive symptoms that may be explained by the improvement of prefrontal brain function in epilepsy.
Kalinin
V V
VV
Zheleznova
E V
EV
Sokolova
L V
LV
Zemlianaia
A A
AA
D000293:Adolescent; D000328:Adult; D000368:Aged; D000927:Anticonvulsants / Q000008:administration & dosage / Q000627:therapeutic use*; D003071:Cognition / Q000187:drug effects* / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D004569:Electroencephalography / Q000379:methods; D004833:Epilepsy, Temporal Lobe / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D005260:Female; D005500:Follow-Up Studies; D005632:Fructose / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D011594:Psychometrics / Q000379:methods*; D000077236:Topiramate; D016896:Treatment Outcome; D055815:Young Adult
D000927:Anticonvulsants; D000077236:Topiramate; D005632:Fructose